Dechra has received FDA approval for CosACTHen® (cosyntropin injection), the first and only cosyntropin specifically approved for use in dogs. The product is designed to support ACTH stimulation testing for the diagnosis and monitoring of canine Cushing’s and Addison’s disease.
Pegasus Laboratories has received FDA conditional approval for Liavium®-CA1, the first veterinary pregabalin product indicated for Chiari-like malformation and syringomyelia in dogs, offering veterinarians a new option for managing chronic neuropathic pain.
Authorization allows veterinarians to use NexGard® and NexGard® COMBO to treat New World screwworm infestations amid spread in Mexico.
Merck Animal Health has received FDA approval for NUMELVI™ (atinvicitinib tablets), the first and only second-generation JAK inhibitor indicated for control of pruritus associated with allergic dermatitis in dogs six months of age and older.
The FDA has conditionally approved Anivive’s Laverdia-CA1 (verdinexor), the first oral SINE-based therapy designed for canine lymphoma, expanding at-home treatment options for both B-cell and T-cell disease.
Loyal has reached a major regulatory milestone as the FDA accepts the Target Animal Safety section for LOY-002, bringing the company closer to launching the first drug intended to extend the healthy lifespan of dogs.
Elanco has received USDA approval for TruCan™ Ultra B (Oral), the first ½ mL oral Bordetella bronchiseptica vaccine for dogs, designed to deliver proven protection with improved patient comfort.
Elanco Animal Health has received U.S. Department of Agriculture (USDA) approval for Befrena™ (tirnovetmab), an anti-IL31 monoclonal antibody injection providing long-lasting relief for dogs suffering from allergic and atopic dermatitis.
The FDA has granted full approval for Vetmedin (pimobendan) to delay the onset of congestive heart failure in dogs with preclinical myxomatous mitral valve disease—the first animal drug indication to transition from expanded conditional to full approval.
Elanco Animal Health has received full approval from the U.S. Department of Agriculture for Trutect™ (formerly CPMA), the first and only monoclonal antibody therapy proven to treat—and now prevent—deadly canine parvovirus.
Sign up for free to receive the latest veterinary news, product announcements, and industry developments.